STX11 is associated with a favorable prognosis in patients with BC and facilitates M1 polarization, and macrophages overexpressing STX11 can inhibit BC malignancy by regulating the PI3K–AKT pathway, suggesting its role as a potential immunotherapeutic candidate. The gene discussed is AKT1; the disease is breast cancer.